Table 2.
Change in laboratory data between at the start and after 2 years of the administration of sodium–glucose cotransporter 2 inhibitors
| At the start | After 2 years | P‐value | |
|---|---|---|---|
| Bodyweight, kg (n = 85) | 71.3 ± 1.67 | 68.3 ± 1.62 | <0.001 |
| Body mass index, kg/m2 (n = 85) | 27.7 ± 0.58 | 26.6 ± 0.56 | <0.001 |
| Systolic BP, mmHg (n = 82) | 130.2 ± 1.93 | 126.7 ± 2.00 | 0.13 |
| Diastolic BP, mmHg (n = 82) | 70.0 ± 1.32 | 68.3 ± 1.35 | 0.28 |
| HbA1c, % (n = 84) | 8.0 ± 0.14 | 7.7 ± 0.10 | 0.04 |
| PG, mg/dL (n = 84) | 189.6 ± 7.29 | 169.1 ± 6.03 | 0.005 |
| eGFR, mL/min/1.73 m2 (n = 85) | 47.1 ± 1.06 | 46.6 ± 1.32 | 0.63 |
| Log‐transformed UACR, mg/g Cr (n = 81) | 2.02 ± 0.09 | 1.93 ± 0.10 | 0.18 |
| Log‐transformed UACR (mg/g Cr), UACR ≥30 mg/g Cr at baseline (n = 53) | 2.55 ± 0.07 | 2.38 ± 0.10 | 0.04 |
Date presented as mean ± standard error. Paired t‐test.
BP, blood pressure; Cr, creatinine; eGFR, estimated glomerular filtration rate; HbA1c, glycated hemoglobin; PG, plasma glucose; SE, standard error; UACR, urinary albumin/creatinine ratio.